Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2014

View Archived Issues

Protein silencing via targeted ubiquitination

Southwest Research Institute receives contract extension for cyanide antidote

Merck & Co. licenses NanoBio's adjuvant technology for use in RSV and influenza vaccines

Novartis presents data for the nAChR partial agonist AQW-051

Merck & Co. presents preclinical and phase I data for MK-1064

Scientists at Roche design novel LPA1 receptor antagonists

VITA contract supports Pulmokine's development of PDGF receptor inhibitor for PAH

Phase III fertility study of Pergoveris in poor ovarian responders begins

Halozyme reports topline data from phase I/II study of HTI-501 for cellulite

Phase II study investigates MLN-0128 for advanced CRPC

Genentech initiates phase I study of DLYE-5953A for refractory solid tumors

Phase II study investigates CPX-351 for relapsed/refractory higher risk MDS and AML

Subcutaneous MabThera approved in Europe for two forms of NHL

EMA validates MolMed's TK cell/gene therapy submission for conditional approval

Pivotal phase III Kiobrina study does not meet primary endpoint

Novel BTK inhibitors patented by Principia Biopharma

GSK withdraws MAA for combined use of Mekinist and Tafinlar

BioNumerik Pharmaceuticals divulges new camptothecin analogues

Neotope Biosciences discloses new anti-MCAM MAbs

AM-Pharma reports phase I data for recombinant human alkaline phosphatase

Baxter to create two separate global healthcare companies

RG-7813 enters first clinical trial for cancer

FDA committee votes against approval of Novartis's RLX-030 for AHF

European Commission approves Latuda for schizophrenia

FDA approves Alprolix for hemophilia B

TAS-205, a novel H-PGDS inhibitor with promising activity in animal models of allergic rhinitis

Terbinafine transungual solution active in a phase IIb study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...